Inari Medical - With superiors outcomes

Announcing the positive results from PEERLESS, a prospective, randomized controlled trial (“RCT”). The data was presented on October 29th by Dr. Wissam Jaber, Professor of Medicine at Emory University School of Medicine and PEERLESS Co-PI, during the Late-Breaking Clinical Trial Sessions at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium.

PEERLESS demonstrated clear superiority for  FlowTriever over CDT, meeting its primary endpoint with a 5-component win ratio of 5.01 (p<0.001). Key outcomes of rapid clot removal with large-bore FlowTriever thrombectomy include:

INTENDED PURPOSE

The FlowTriever Retrieval/Aspiration System’s intended purpose is for use in the peripheral vasculature and pulmonary arteries for the treatment of intermediate- and high-risk pulmonary embolism in patients 18 years or older deemed medically suitable for mechanical thrombectomy. The Intended Purpose of the FlowSaver device is to filter and reinject aspirated blood into patients 18 years or older.

Note: This device is restricted to sale by or on the order of a physician.

Refer to Instructions for Use/Intended Purpose for complete indications for use, contraindications, warnings and precautions.

For all non-Inari products, please refer to manufacturer Instructions for Use/Intended Purpose for complete indications for use, contraindications, warnings and precautions.

All trademarks are property of their respective owners.

Inari Medical, Inc. headquarters: 6001 Oak Canyon, Suite 100 | Irvine CA 92618

Inari Medical Europe GmbH, a subsidiary of Inari Medical, Inc. | Messeplatz 10 | 4058 Basel, Switzerland.

MM-02133_Rev. A_EN_2024-11-05